¼¼°èÀÇ ºñÈæ»öÁ¾ ÇÇºÎ¾Ï Ä¡·á ½ÃÀå º¸°í¼ : Ä¡·á À¯Çü, ÀûÀÀÁõ, ÃÖÁ¾ ¿ëµµ, Áö¿ªº°(2024-2032³â)
Non-Melanoma Skin Cancer Treatment Market Report by Treatment Type, Indication, End Use, and Region 2024-2032
ºñÈæ»öÁ¾ ÇÇºÎ¾Ï Ä¡·á(NMSC, Non-Melanoma Skin Cancer Treatment) ½ÃÀå ±Ô¸ð´Â 2023³â 5¾ï 6,320¸¸ ´Þ·¯¿¡ ´ÞÇß½À´Ï´Ù. IMARC ±×·ìÀº ÇâÈÄ ½ÃÀåÀÌ 2032³â±îÁö 8¾ï 5,010¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óÇßÀ¸¸ç, 2024³â°ú 2032³â »çÀÌ¿¡ 4.5%ÀÇ ¼ºÀå·ü(CAGR)À» º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøÇß½À´Ï´Ù.
ºñÈæ»öÁ¾ ÇǺξÏ(NMSC)Àº ÇǺÎÀÇ »óÃþºÎ¿¡¼ ¾Ç¼º ¼¼Æ÷ÀÇ ÀÌ»ó Áõ½ÄÀ» ¸»ÇÕ´Ï´Ù. NMSCÀÇ ÀϹÝÀûÀÎ À¯ÇüÀ¸·Î´Â ±âÀú¼¼Æ÷¾Ï, ¸ÓŬ¼¼Æ÷¾Ï, ÆíÆò»óÇǾÏ, ÇǺΠT¼¼Æ÷ ¸²ÇÁÁ¾ µîÀÌ ÀÖ½À´Ï´Ù. ÁÖ·Î ÇǺο¡ µüµüÇÑ ¸ÕÁö¿Í ºñ´Ã ¸ð¾çÀÇ ¹ÝÁ¡ÀÌ »ý±â´Â °ÍÀÌ Æ¯Â¡ÀÔ´Ï´Ù. Ä¡·á ¼ö¹ýÀ¸·Î´Â Çö¹Ì°æ ¼ö¼ú, ·¹ÀÌÀú Ä¡·á, µ¿°á ¿ä¹ý µîÀÇ ¿Ü°úÀû óġ¿¡ ÀÇÇÑ ¾Ï¼¼Æ÷ÀÇ Á¦°Å³ª ±¤¼±¿ªÇÐÀû ¿ä¹ý(PDT), ¹æ»ç¼±Ä¡·á, Àü±âÄ¡·á µî ´Ù¾çÇÑ ºñ¼ö¼úÀû Ä¡·á°¡ ÀÖ½À´Ï´Ù.
ÇǺξÏÀÇ À¯º´·ü Áõ°¡¿Í ¼¼°è ³ëÀÎ Àα¸ Áõ°¡°¡ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÏ´Â ÁÖ¿ä ¿äÀÎÀÌ µÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, NMSC¿¡ ´ëÇÑ À̿밡´ÉÇÑ ´ëü Ä¡·á¹ý¿¡ ´ëÇÑ ´ëÁßÀÇ ÀÇ½Ä Áõ°¡µµ ½ÃÀå ¼ºÀåÀ» ÀÚ±ØÇϰí ÀÖ½À´Ï´Ù. ÀüÅëÀûÀ¸·Î »ç¿ëµÇ´Â Ä¡·á¹ý°ú ºñ±³ÇÒ ¶§, Ç¥À缺 ¹æ»ç¼± ¿ä¹ýÀº ȯÀÚÀÇ ½Åü¿¡ ºÎÀÛ¿ëÀÌ Àû°í Çõ½ÅÀûÀÎ ÈÞ´ë¿ë Àåºñ¸¦ »ç¿ëÇÏ¿© ¼öÇà ÇÒ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÀÌ·¯ÇÑ Àåºñ´Â ³ôÀº Á¤È®µµ¿Í °¨µµ·Î ÇǺΠº´º¯ÀÇ Á¶±â Áø´Ü¿¡µµ »ç¿ëµË´Ï´Ù. ¶ÇÇÑ ÀüÀں귢¼¼¶óÇÇ(eBx)ÀÇ °³¹ß µî ´Ù¾çÇÑ ±â¼ú Áøº¸µµ ¼ºÀåÀ» °¡¼ÓÇÏ´Â ¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. eBx´Â ÅëÁõÀÌ ¾ø´Â ºñħ½ÀÀûÀΠǥÀû Àú¿¡³ÊÁö ¹æ»ç¼± ¿ä¹ýÀ̸ç, Ä¡·á ±â°£ÀÌ Âª°í, ÀÌ¿ô °Ç°ÇÑ Á¶Á÷¿¡ ´ëÇÑ ¹æ»ç¼± ³ëÃâÀÇ À§ÇèÀ» ÃÖ¼ÒÈÇÒ ¼ö ÀÖ½À´Ï´Ù. ±× ¹ÛÀÇ ¿äÀÎÀ¸·Î´Â °³ÀÎÀÇ ÇコÄɾî ÁöÃâ Áõ°¡, ÀÓ»ó½ÃÇè¿¡ ´ëÇÑ Á¤ºÎÀÇ ÀÚ±Ý Áö¿ø, ±¤¹üÀ§ÇÑ ¿¬±¸°³¹ß(R&D) Ȱµ¿ µîÀÌ ½ÃÀåÀ» ´õ¿í °ßÀÎÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
ÀÌ º¸°í¼¿¡¼ ´Ù·ç´Â ÁÖ¿ä Áú¹®
- ¼¼°èÀÇ ºñÈæ»öÁ¾ ÇÇºÎ¾Ï Ä¡·á ½ÃÀåÀº Áö±Ý±îÁö ¾î¶»°Ô ÃßÀÌÇßÀ¸¸ç, ÇâÈÄ ¾î¶»°Ô ÃßÀÌÇØ ³ª°¥ °ÍÀΰ¡?
- COVID-19´Â ¼¼°èÀÇ ºñÈæ»öÁ¾ ÇÇºÎ¾Ï Ä¡·á ½ÃÀå¿¡ ¾î¶² ¿µÇâÀ» ¹ÌÃÆ´Â°¡?
- ÁÖ¿ä Áö¿ª ½ÃÀåÀº?
- Ä¡·á À¯Çüº° ½ÃÀå ºÐ¼®Àº?
- ÀûÀÀÁõº° ½ÃÀå ºÐ¼®Àº?
- ÃÖÁ¾ ¿ëµµ¿¡ µû¸¥ ½ÃÀå ºÐ¼®Àº?
- »ê¾÷ ¹ë·ùüÀÎÀÇ ´Ù¾çÇÑ ´Ü°è¶õ?
- »ê¾÷ÀÇ ÁÖ¿ä ÃËÁø¿äÀÎ ¹× µµÀüÀº ¹«¾ùÀΰ¡?
- ¼¼°èÀÇ ºñÈæ»öÁ¾ ÇÇºÎ¾Ï Ä¡·á ½ÃÀåÀÇ ±¸Á¶ ¹× ÁÖ¿ä ±â¾÷Àº?
- »ê¾÷ °æÀïµµ´Â?
¸ñÂ÷
Á¦1Àå ¼¹®
Á¦2Àå Á¶»ç ¹üÀ§ ¹× Á¶»ç ¹æ¹ý
- Á¶»ç ¸ñÀû
- ÀÌÇØ°ü°èÀÚ
- µ¥ÀÌÅÍ ¼Ò½º
- ½ÃÀå ÃßÁ¤
- Á¶»ç ¹æ¹ý
Á¦3Àå ÁÖ¿ä ¿ä¾à
Á¦4Àå ¼Ò°³
Á¦5Àå ¼¼°èÀÇ ºñÈæ»öÁ¾ ÇÇºÎ¾Ï Ä¡·á ½ÃÀå
- ½ÃÀå °³¿ä
- ½ÃÀå ½ÇÀû
- COVID-19ÀÇ ¿µÇâ
- ½ÃÀå ¿¹Ãø
Á¦6Àå ½ÃÀå ³»¿ª : Ä¡·á À¯Çüº°
- ÈÇпä¹ý
- ¹æ»ç¼±Ä¡·á
- ±¤¼±¿ªÇпä¹ý
- ±âŸ
Á¦7Àå ½ÃÀå ºÐ¼® : ÀûÀÀÁõº°
- ±âÀú¼¼Æ÷¾Ï
- T¼¼Æ÷ ¸²ÇÁÁ¾
- ÆíÆò»óÇǾÏ
- ±âŸ
Á¦8Àå ½ÃÀå ³»¿ª : ÃÖÁ¾ ¿ëµµº°
- º´¿ø
- Àü¹® Ŭ¸®´Ð
- ¿Ü·¡¼ö¼ú¼¾ÅÍ(ASC)
- ±âŸ
Á¦9Àå ½ÃÀå ºÐ¼® : Áö¿ªº°
- ºÏ¹Ì
- ¾Æ½Ã¾Æ ÅÂÆò¾ç
- Áß±¹
- ÀϺ»
- Àεµ
- Çѱ¹
- È£ÁÖ
- Àεµ³×½Ã¾Æ
- ±âŸ
- À¯·´
- µ¶ÀÏ
- ÇÁ¶û½º
- ¿µ±¹
- ÀÌÅ»¸®¾Æ
- ½ºÆäÀÎ
- ·¯½Ã¾Æ
- ±âŸ
- ³²¹Ì
- Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
- ½ÃÀå µ¿Çâ
- ½ÃÀå ºÐ¼® : ±¹°¡º°
- ½ÃÀå ¿¹Ãø
Á¦10Àå SWOT ºÐ¼®
Á¦11Àå ¹ë·ùüÀÎ ºÐ¼®
Á¦12Àå Porter's Five Forces ºÐ¼®
- °³¿ä
- ±¸¸ÅÀÚÀÇ Çù»ó·Â
- °ø±Þ±â¾÷ÀÇ Çù»ó·Â
- °æÀïµµ
- ½Å±Ô Âü°¡¾÷üÀÇ À§Çù
- ´ëüǰÀÇ À§Çù
Á¦13Àå °¡°Ý ºÐ¼®
Á¦14Àå °æÀï ±¸µµ
- ½ÃÀå ±¸Á¶
- ÁÖ¿ä ±â¾÷
- ÁÖ¿ä ±â¾÷ ÇÁ·ÎÆÄÀÏ
- Accuray Incorporated
- Almirall SA
- Boehringer Ingelheim GmbH
- Bristol-Myers Squibb Company
- Elekta AB
- Eli Lilly and Company
- F. Hoffmann-La Roche AG
- Icad Inc.
- Merck & Co. Inc.
- Novartis AG
- Sun Pharmaceutical Industries Limited
- Varian Medical Systems Inc.
LYJ
The global non-melanoma skin cancer treatment market size reached US$ 563.2 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 850.1 Million by 2032, exhibiting a growth rate (CAGR) of 4.5% during 2024-2032.
Non-melanoma skin cancer (NMSC) refers to the abnormal growth of malignant cells in the upper layer of the skin. Some of the common types of NMSC include basal cell, merkle cell and squamous cell carcinoma and cutaneous T-cell lymphoma. It is primarily characterized by the development of firm lumps or scaly patches on the skin. The treatment methodologies involve the removal of cancer cells through surgical procedures, including micrographic surgery, laser therapy and cryotherapy, and various non-surgical treatments, such as photodynamic therapy (PDT), radiotherapy and electrotherapy.
The increasing prevalence of skin cancer and the rising geriatric population across the globe, represent as the key factors driving the growth of the market. Furthermore, rising awareness among the masses regarding the available treatment alternatives for NMSC is also stimulating the market growth. In comparison to the traditionally used therapies, superficial radiation therapy has reduced side-effects on the patient's body and can be conducted through innovative portable devices. These devices are also used for early diagnosis of skin lesions with high accuracy and sensitivity. Additionally, various technological advancements, such as the development of electronic brachytherapy (eBx), are acting as other growth-inducing factors. eBx is a painless and non-invasive targeted low-energy radiation therapy that requires a shorter treatment course and minimizes the risks of radiation exposure to the nearby healthy tissues. Other factors, including rising healthcare expenditures of individuals and government funding for clinical trials, along with extensive research and development (R&D) activities, are anticipated to drive the market further.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each segment of the global non-melanoma skin cancer treatment market report, along with forecasts at the global, regional and country levels from 2024-2032. Our report has categorized the market based on treatment type, indication and end use.
Breakup by Treatment Type:
Chemotherapy
Radiation Therapy
Photodynamic Therapy
Others
Breakup by Indication:
Basal Cell Carcinoma
T-Cell Lymphoma
Squamous Cell Carcinoma
Others
Breakup by End Use:
Hospitals
Specialty Clinics
Ambulatory Surgery Centers
Others
Breakup by Region:
North America
United States
Canada
Asia Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
Competitive Landscape:
The report has also analysed the competitive landscape of the market with some of the key players being Accuray Incorporated, Almirall S.A., Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Elekta AB, Eli Lilly and Company, F. Hoffmann-La Roche AG, Icad Inc., Merck & Co. Inc., Novartis AG, Sun Pharmaceutical Industries Limited and Varian Medical Systems Inc.
Key Questions Answered in This Report:
- How has the global non-melanoma skin cancer treatment market performed so far and how will it perform in the coming years?
- What has been the impact of COVID-19 on the global non-melanoma skin cancer treatment market?
- What are the key regional markets?
- What is the breakup of the market based on the treatment type?
- What is the breakup of the market based on the indication?
- What is the breakup of the market based on the end use?
- What are the various stages in the value chain of the industry?
- What are the key driving factors and challenges in the industry?
- What is the structure of the global non-melanoma skin cancer treatment market and who are the key players?
- What is the degree of competition in the industry?
Table of Contents
1 Preface
2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
5 Global Non-Melanoma Skin Cancer Treatment Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
6 Market Breakup by Treatment Type
- 6.1 Chemotherapy
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
- 6.2 Radiation Therapy
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
- 6.3 Photodynamic Therapy
- 6.3.1 Market Trends
- 6.3.2 Market Forecast
- 6.4 Others
- 6.4.1 Market Trends
- 6.4.2 Market Forecast
7 Market Breakup by Indication
- 7.1 Basal Cell Carcinoma
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
- 7.2 T-Cell Lymphoma
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
- 7.3 Squamous Cell Carcinoma
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
- 7.4 Others
- 7.4.1 Market Trends
- 7.4.2 Market Forecast
8 Market Breakup by End Use
- 8.1 Hospitals
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
- 8.2 Specialty Clinics
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
- 8.3 Ambulatory Surgery Centers
- 8.3.1 Market Trends
- 8.3.2 Market Forecast
- 8.4 Others
- 8.4.1 Market Trends
- 8.4.2 Market Forecast
9 Market Breakup by Region
- 9.1 North America
- 9.1.1 United States
- 9.1.1.1 Market Trends
- 9.1.1.2 Market Forecast
- 9.1.2 Canada
- 9.1.2.1 Market Trends
- 9.1.2.2 Market Forecast
- 9.2 Asia Pacific
- 9.2.1 China
- 9.2.1.1 Market Trends
- 9.2.1.2 Market Forecast
- 9.2.2 Japan
- 9.2.2.1 Market Trends
- 9.2.2.2 Market Forecast
- 9.2.3 India
- 9.2.3.1 Market Trends
- 9.2.3.2 Market Forecast
- 9.2.4 South Korea
- 9.2.4.1 Market Trends
- 9.2.4.2 Market Forecast
- 9.2.5 Australia
- 9.2.5.1 Market Trends
- 9.2.5.2 Market Forecast
- 9.2.6 Indonesia
- 9.2.6.1 Market Trends
- 9.2.6.2 Market Forecast
- 9.2.7 Others
- 9.2.7.1 Market Trends
- 9.2.7.2 Market Forecast
- 9.3 Europe
- 9.3.1 Germany
- 9.3.1.1 Market Trends
- 9.3.1.2 Market Forecast
- 9.3.2 France
- 9.3.2.1 Market Trends
- 9.3.2.2 Market Forecast
- 9.3.3 United Kingdom
- 9.3.3.1 Market Trends
- 9.3.3.2 Market Forecast
- 9.3.4 Italy
- 9.3.4.1 Market Trends
- 9.3.4.2 Market Forecast
- 9.3.5 Spain
- 9.3.5.1 Market Trends
- 9.3.5.2 Market Forecast
- 9.3.6 Russia
- 9.3.6.1 Market Trends
- 9.3.6.2 Market Forecast
- 9.3.7 Others
- 9.3.7.1 Market Trends
- 9.3.7.2 Market Forecast
- 9.4 Latin America
- 9.4.1 Brazil
- 9.4.1.1 Market Trends
- 9.4.1.2 Market Forecast
- 9.4.2 Mexico
- 9.4.2.1 Market Trends
- 9.4.2.2 Market Forecast
- 9.4.3 Others
- 9.4.3.1 Market Trends
- 9.4.3.2 Market Forecast
- 9.5 Middle East and Africa
- 9.5.1 Market Trends
- 9.5.2 Market Breakup by Country
- 9.5.3 Market Forecast
10 SWOT Analysis
- 10.1 Overview
- 10.2 Strengths
- 10.3 Weaknesses
- 10.4 Opportunities
- 10.5 Threats
11 Value Chain Analysis
12 Porters Five Forces Analysis
- 12.1 Overview
- 12.2 Bargaining Power of Buyers
- 12.3 Bargaining Power of Suppliers
- 12.4 Degree of Competition
- 12.5 Threat of New Entrants
- 12.6 Threat of Substitutes
13 Price Analysis
14 Competitive Landscape
- 14.1 Market Structure
- 14.2 Key Players
- 14.3 Profiles of Key Players
- 14.3.1 Accuray Incorporated
- 14.3.1.1 Company Overview
- 14.3.1.2 Product Portfolio
- 14.3.1.3 Financials
- 14.3.1.4 SWOT Analysis
- 14.3.2 Almirall S.A.
- 14.3.2.1 Company Overview
- 14.3.2.2 Product Portfolio
- 14.3.2.3 Financials
- 14.3.2.4 SWOT Analysis
- 14.3.3 Boehringer Ingelheim GmbH
- 14.3.3.1 Company Overview
- 14.3.3.2 Product Portfolio
- 14.3.3.3 SWOT Analysis
- 14.3.4 Bristol-Myers Squibb Company
- 14.3.4.1 Company Overview
- 14.3.4.2 Product Portfolio
- 14.3.4.3 Financials
- 14.3.4.4 SWOT Analysis
- 14.3.5 Elekta AB
- 14.3.5.1 Company Overview
- 14.3.5.2 Product Portfolio
- 14.3.5.3 Financials
- 14.3.5.4 SWOT Analysis
- 14.3.6 Eli Lilly and Company
- 14.3.6.1 Company Overview
- 14.3.6.2 Product Portfolio
- 14.3.6.3 Financials
- 14.3.6.4 SWOT Analysis
- 14.3.7 F. Hoffmann-La Roche AG
- 14.3.7.1 Company Overview
- 14.3.7.2 Product Portfolio
- 14.3.7.3 SWOT Analysis
- 14.3.8 Icad Inc.
- 14.3.8.1 Company Overview
- 14.3.8.2 Product Portfolio
- 14.3.8.3 Financials
- 14.3.8.4 SWOT Analysis
- 14.3.9 Merck & Co. Inc.
- 14.3.9.1 Company Overview
- 14.3.9.2 Product Portfolio
- 14.3.9.3 Financials
- 14.3.9.4 SWOT Analysis
- 14.3.10 Novartis AG
- 14.3.10.1 Company Overview
- 14.3.10.2 Product Portfolio
- 14.3.10.3 Financials
- 14.3.10.4 SWOT Analysis
- 14.3.11 Sun Pharmaceutical Industries Limited
- 14.3.11.1 Company Overview
- 14.3.11.2 Product Portfolio
- 14.3.11.3 Financials
- 14.3.11.4 SWOT Analysis
- 14.3.12 Varian Medical Systems Inc.
- 14.3.12.1 Company Overview
- 14.3.12.2 Product Portfolio
- 14.3.12.3 Financials
- 14.3.12.4 SWOT Analysis